Charuka D Wickramasinghe

Assistant Professor of Applied Mathematics

Northern Kentucky University
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (8)

Year:

2026

Year:

2026

Year:

2026

Quantitative understanding of drug penetration and exposure in the human central nervous system (CNS) and brain tumors is essential for the rational development of new drugs and optimal use of existing drugs for brain cancer. To address this need, we developed and validated a novel 9‐compartment permeability‐limited CNS (9‐CNS) physiologically based pharmacokinetic (PBPK) model, enabling mechanistic and quantitative prediction of spatial pharmacokinetics for systemically administered small‐molecule drugs across different regions of the human brain, cerebrospinal fluid, and brain tumors. To make the 9‐CNS model accessible to a broad range of users, we developed the SpatialCNS‐PBPK app, a user‐friendly, web‐based R/Shiny platform built with R and Shiny programming. The app provides key functionalities for model simulation, sensitivity analysis, and pharmacokinetic parameter calculation. This tutorial introduces the development and evaluation of the SpatialCNS‐PBPK app, highlights its key features and functions, and provides a step‐by‐step user guide for practical applications. By enhancing our ability to predict the spatial pharmacokinetics of anticancer drugs in the human CNS and brain tumors, the SpatialCNS‐PBPK app serves as an invaluable computational tool and data‐driven approach for advancing drug development and optimizing treatment strategies for more effective treatment of brain cancer.

Year:

2025

Background: This study aimed to develop a population pharmacokinetic (PK) model that characterized the plasma concentration–time profiles of the total and unbound pamiparib, a PARP inhibitor, in glioblastoma patients and identified patient factors influencing the PK. Methods: The total and unbound pamiparib plasma concentration data were obtained from 41 glioblastoma patients receiving 60 mg of pamiparib twice daily. Nonlinear mixed-effects modeling was performed using Monolix (2024R1) to simultaneously fit the total and unbound drug plasma concentration data. The covariate model was developed by covariate screening using generalized additive modeling followed by stepwise covariate modeling. Model simulations were performed following oral doses of 10–60 mg BID. Results: The total and unbound pamiparib plasma concentration–time profiles were best described by a one-compartment model with first-order absorption and elimination. Creatinine clearance and age were the significant covariates on the apparent volume of distribution (V/F) and apparent clearance (CL/F), respectively, explaining ~22% and ~5% of IIV of V/F and CL/F. Population estimates of the absorption rate constant (Ka), V/F, CL/F, and unbound fraction for the total drug were 1.58 h−1, 44 L, 2.59 L/h, and 0.041. Model simulations suggested that doses as low as 20 mg BID may be adequate for therapeutic effects in a general patient population, assuming that a target engagement ratio (i.e., unbound Css,min/IC50) of 5 or above is sufficient for full target engagement. Conclusions: The total and unbound pamiparib plasma PK are well characterized by a linear one-compartment model, with creatinine clearance as the significant covariate on V/F. Model simulations support further clinical investigation into dose reduction to optimize the benefit-to-risk ratio of pamiparib, particularly in combination therapies.

Year:

2025

Direct measurement of spatial–temporal drug penetration and exposure in the human central nervous system (CNS) and brain tumors is difficult or infeasible. This study aimed to develop an innovative mechanistic modeling platform for quantitative prediction of spatial pharmacokinetics of systemically administered drugs in the human CNS and brain tumors. A nine‐compartment CNS (9‐CNS) physiologically‐based pharmacokinetic model was developed to account for general anatomical structure and pathophysiological heterogeneity of the human CNS and brain tumors. Drug distribution into and within the CNS and tumors is driven by plasma concentration–time profiles and governed by drug properties and CNS pathophysiology. The model was validated by comparisons of model predictions and clinically observed data of six drugs (abemaciclib, ribociclib, pamiparib, olaparib, temuterkib, and ceritinib) in glioblastoma patients. As rigorously validated, the 9‐CNS model allows reliable prediction of spatial pharmacokinetics in different regions of the brain parenchyma (i.e., parenchyma adjacent to CSF and deep parenchyma), tumors (i.e., tumor rim, bulk tumor, and tumor core), and CSF (i.e., ventricular CSF, cranial and spinal subarachnoid CSF). By considering inter‐individual plasma pharmacokinetic variability and CNS/tumor heterogeneity, the model well predicts the inter‐individual variability and spatial heterogeneity of drug exposure in the CNS and tumors as observed for all six drugs in glioblastoma patients. The 9‐CNS model is a first‐of‐its kind, mechanism‐based computational modeling platform that enables early reliable prediction of spatial CNS and tumor pharmacokinetics based on plasma concentration–time profiles. It provides a valuable tool to assist rational drug development and treatment for brain cancer.

Year:

2025

Year:

2024

Year:

2024

Collaborators (4)

Jing Li

Professor

Karmanos Cancer Institute

UNITED STATES
View details

Seongho Kim

Professor of Biostatistics

Wayne State University School of Medicine

UNITED STATES
View details

Artak Tovmasyan

Research Assistant Professor

University of Arizona College of Medicine

UNITED STATES
View details

Xun Bao

Assistant Professor-Research

Stanford Health Care

UNITED STATES
View details